Minnesota Medical Technologies has raised US$20.6m to launch its StaySure device for fecal incontinence in the US, offering an alternative to absorbent products.
The company, founded in 2015, developed StaySure in collaboration with Mayo Clinic gastroenterologist Adil Bharucha. The single-use device is intended as an alternative to absorbent products such as adult nappies and pads, which have historically dominated management of the condition.
Fecal incontinence, often referred to as accidental bowel leakage, affects more than 2 per cent of the global population, representing tens of millions of people worldwide. Many people with the condition rely on adult nappies and pads rather than restorative solutions.
Following the successful completion of a clinical trial at Mayo Clinic and the establishment of a medical device manufacturing facility, the US Food and Drug Administration granted clearance for StaySure in July 2025.
The company said the new funding will support commercial and distribution infrastructure for the US launch, expand sales, marketing and customer care teams, and reduce debt.
The Series A round was co-led by HM Venture Partners, a San Francisco-based venture capital firm backing medtech and biotech companies, and Southeast Minnesota Capital Partners, a Rochester-based firm focused on Minnesota medtech companies.
chief executive officer David A. Jonas said: “This funding marks a pivotal moment for our company. With the support of our investors, we are now positioned to launch StaySure into the newly cleared US market and expand our talented team. For the millions of people living with fecal incontinence, this represents an opportunity to finally access a safe, effective, and life-changing solution.”
